CEO, Nextmed Capital
is an early stage life science VC firm and advises three medical
device start or scale-up companies. Founded in 2016, its mission
is to nurture the seeds of the next generation of medical
innovation with the goal of becoming Australia's leading very
early stage innovation and medical technology investor. NextMed
Capital provides support to researchers seeking funds and
expertise to accelerate commercialisation of technology. The
company invests in projects as early as the pre-clinical phase
and adds significant value to its investments through leveraging
the combined commercial, entrepreneurial, project management,
financing, business planning and academic skills of its
experienced management team.
a unique education and experience to the life science field.
Following bachelor degrees in Genetics, Accounting and Finance,
Michael joined Macquarie Group and spend 13 years as an
investment banker, funds manager and project manager working in
Melbourne, Seoul, Moscow, Almaty, and London. During this time,
he invested more than $2 billion and ultimately established of a
start-up company in Kazakhstan and executive roles in
pre-revenue project in Philippines. After returning to
Australia, Michael sought to apply his extensive strategic,
commercial, financial and project management expertise to his
passion for the life science sector where he has been advising
as well as investing in early stage companies primarily focused
on medical devices and artificial intelligence projects.
Currently Michael holds a number of non-executive directorship
roles, leads NextMed Capital.